AuT-1

About Authera

Authera is a science-driven biotech founded in 2022, building on decades of foundational research in FcRn biology from its academic founders. The company operates a cutting-edge technology platform that integrates biochemical, cellular, and in vivo models to de-risk the development of novel biologics with fine-tuned FcRn interactions. With a lead program in pre-clinical development for severe eye diseases and recent non-dilutive grant funding, Authera is positioned to advance its pipeline while seeking strategic partnerships to explore the broad therapeutic utility of its platform.

About Authera

Authera leverages deep scientific expertise in FcRn biology to de-risk and accelerate the development of next-generation biologics. Founded in 2022 by a team of renowned academics and entrepreneurs, the company has secured non-dilutive grant funding to advance its lead candidate, AuT-1, for severe eye diseases. Authera's strategy combines advancing its own pipeline with establishing science-driven partnerships to explore the broad therapeutic potential of its FcRn-focused platform.

Therapeutic Areas